Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.904508
Reference25 articles.
1. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
2. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
3. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China;Therapeutic Advances in Hematology;2024-01
2. Feasibility of treatment-free remission with generic imatinib;Indian Journal of Medical Research;2023-01
3. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs;Blood Advances;2021-09-03
4. Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study;BLOOD RESEARCH;2020-09-30
5. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States;Cancer Medicine;2019-09-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3